Quality of life during potentially curative treatment for locally advanced oesophageal cancer

被引:67
作者
Avery, K. N. L.
Metcalfe, C.
Barham, C. P.
Alderson, D.
Falk, S. J.
Blazeby, J. M. [1 ]
机构
[1] Bristol Royal Infirm & Gen Hosp, Clin Sci S Bristol, Bristol BS2 8HW, Avon, England
[2] Univ Bristol, Dept Social Med, Bristol BS8 1TH, Avon, England
[3] Univ Bristol, United Bristol Hlth Care Trust, Bristol BS8 1TH, Avon, England
关键词
D O I
10.1002/bjs.5888
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Combination chemoradiotherapy with or without surgery are internationally applied alternative strategies for potential cure of oesophageal cancer. This study compared health-related quality of life (HRQL) between patients selected for chemoradiation and those who had combination treatment including oesophagectomy. Methods: Patients with stage II or III oesophageal cancer completed HRQL assessments at baseline, at the worst expected HRQL time point and at expected recovery. HRQL was compared between groups using linear regression, adjusting for age, sex, performance status, turnout stage and type, and baseline HRQL. Results: Some 132 patients began treatment, of whom 51 had chemoradiotherapy and 81 combination treatment including surgery. Patients selected for chemoradiotherapy were older, more likely to have squamous cell cancer and reported poorer HRQL than those selected for surgery. At the worst expected time point after treatment, both groups reported multiple symptoms and poor function, but surgery was associated with a greater reduction in HRQL from baseline than chemoradiotherapy. Recovery of HRQL was achieved within 6 months after chemoradiotherapy, but complete recovery had not occurred 6 months after surgery and there was persistent significant deterioration in some aspects. Conclusion: The negative treatment-related impact of chemoradiation on short-term HRQL is less than that experienced with combination treatment including surgery. Patients preferring early recovery should consider definitive chemoradiation.
引用
收藏
页码:1369 / 1376
页数:8
相关论文
共 27 条
[1]   THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].
AARONSON, NK ;
AHMEDZAI, S ;
BERGMAN, B ;
BULLINGER, M ;
CULL, A ;
DUEZ, NJ ;
FILIBERTI, A ;
FLECHTNER, H ;
FLEISHMAN, SB ;
DEHAES, JCJM ;
KAASA, S ;
KLEE, M ;
OSOBA, D ;
RAZAVI, D ;
ROFE, PB ;
SCHRAUB, S ;
SNEEUW, K ;
SULLIVAN, M ;
TAKEDA, F .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376
[2]  
Bancewicz J, 2002, LANCET, V359, P1727
[3]   Health-related quality of life measurement in randomized clinical trials in surgical oncology [J].
Blazeby, Jane M. ;
Avery, Kerry ;
Sprangers, Mirjam ;
Pikhart, Hynek ;
Fayers, Peter ;
Donovan, Jenny .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (19) :3178-3186
[4]   Analysis of clinical decision-making in multi-disciplinary cancer teams [J].
Blazeby, JM ;
Wilson, L ;
Metcalfe, C ;
Nicklin, J ;
English, R ;
Donovan, JL .
ANNALS OF ONCOLOGY, 2006, 17 (03) :457-460
[5]   Health-related quality of life during neoadjuvant treatment and surgery for localized esophageal carcinoma [J].
Blazeby, JM ;
Sanford, E ;
Falk, SJ ;
Alderson, D ;
Donovan, JL .
CANCER, 2005, 103 (09) :1791-1799
[6]   Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer [J].
Blazeby, JM ;
Conroy, T ;
Hammerlid, E ;
Fayers, P ;
Sezer, O ;
Koller, M ;
Arraras, J ;
Bottomley, A ;
Vickery, CW ;
Etienne, PL ;
Alderson, D .
EUROPEAN JOURNAL OF CANCER, 2003, 39 (10) :1384-1394
[7]   Development of an EORTC questionnaire module to be used in quality of life assessment for patients with oesophageal cancer [J].
Blazeby, JM ;
Alderson, D ;
Winstone, K ;
Steyn, R ;
Hammerlid, E ;
Arraras, J ;
Farndon, JR .
EUROPEAN JOURNAL OF CANCER, 1996, 32A (11) :1912-1917
[8]  
Blazeby JM, 2000, CANCER, V88, P1781
[9]   A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102):: chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable thoracic esophageal cancer [J].
Bonnetain, F ;
Bouché, O ;
Michel, P ;
Mariette, C ;
Conroy, T ;
Pezet, D ;
Roullet, B ;
Seitz, JF ;
Paillot, B ;
Arveux, P ;
Milan, C ;
Bedenne, L .
ANNALS OF ONCOLOGY, 2006, 17 (05) :827-834
[10]   Communicating quality of life information to cancer patients: A study of six presentation formats [J].
Brundage, M ;
Feldman-Stewart, D ;
Leis, A ;
Bezjak, A ;
Degner, L ;
Velji, K ;
Zetes-Zanatta, L ;
Tu, D ;
Ritvo, P ;
Pater, J .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) :6949-6956